A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma

<div>The prognosis significance of the expressions of PCBP1-AS1 in LUAD sufferers. (a) Survival probability of 512 LUAD patients separated into 2 groups on the foundation of the mean expression of PCBP1-AS1. (b, c) Univariable and multivariable analyses of OS in LSCC sufferers.</div>

Journal of Immunology Research

fig2

Figure 2

Figure 2: A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma 